PFIZER HIGHLIGHTING ZIPRASIDONE LOWER WEIGHT GAIN IN SCHIZOPHRENICS COMPARED TO LILLY ZYPREXA; TROVAFLOXACIN NDA FILING FOR 12 INDICATIONS SET FOR DECEMBER
Ziprasidone's lower incidence of weight gain relative to Lilly's recently approved Zyprexa will be emphasized in marketing of the anti-psychotic, Pfizer President-Central Research George Milne told a securities analysts meeting in New York City Oct. 28.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth